相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors
Lorenzo Gervaso et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
S. -A. Im et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2-Metastatic Breast Cancer: Biological Mechanisms and New Treatments
Daniele Presti et al.
CANCERS (2019)
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cyclin-Dependent Kinase Inhibitor-Associated Thromboembolism
Sven R. Olson et al.
JAMA ONCOLOGY (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
L. Malorni et al.
ANNALS OF ONCOLOGY (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
Luca Gianni et al.
LANCET ONCOLOGY (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study
Grigoris T. Gerotziafas et al.
ONCOLOGIST (2017)
Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis
Umair T. Khan et al.
BMC CANCER (2017)
Targeted therapies in breast cancer: New challenges to fight against resistance
Viviana Masoud et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2017)
When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data
Alex J. Walker et al.
BLOOD (2016)
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
G. Curigliano et al.
BREAST (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
The Role of CDK4/6 Inhibition in Breast Cancer
Conleth G. Murphy et al.
ONCOLOGIST (2015)
Incidence of venous thromboembolism in patients with cancer - A cohort study using linked United Kingdom databases
Alex J. Walker et al.
EUROPEAN JOURNAL OF CANCER (2013)
Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006
D. P. Cronin-Fenton et al.
BRITISH JOURNAL OF CANCER (2010)
Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status
Veronica Wendy Setiawan et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Development and validation of a predictive model for chemotherapy-associated thrombosis
Alok A. Khorana et al.
BLOOD (2008)
Incidence of venous thromboembolism and the impact on survival in breast cancer patients
Helen K. Chew et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study
AA Khorana et al.
CANCER (2005)
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma - A prospectively planned combined survival analysis of two multicenter trials
A Howell et al.
CANCER (2005)
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Howell et al.
LANCET (2005)
The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma - A systematic review
SR Deitcher et al.
CANCER (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Thrombosis -: a clue of poor prognosis in primary non-metastatic breast cancer?
GF von Tempelhoff et al.
BREAST CANCER RESEARCH AND TREATMENT (2002)
分享论文
